What is the risk posed by prostate cancer?

Journal of the National Cancer Institute - Monographs

Volumn , Issue 45, 2012, Pages 169-174

  Albertsen, Peter C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; DISEASE SEVERITY; GLEASON SCORE; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SURVIVAL RATE; TUMOR VOLUME; CANCER GRADING; EARLY DIAGNOSIS; MALE; PROGNOSIS; PROSTATE TUMOR; RISK; TREATMENT OUTCOME;

EARLY DETECTION OF CANCER; HUMANS; MALE; NEOPLASM GRADING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84871786734     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgs028     Document Type: Article

References (32)

1. Thompson H. The Enlarged Prostate. London: John Churchill Company; 1852.
2. Levin I, Sittenfield MJ. On the mechanism of the formation of metastases in malignant tumors: an experimental study. J Exp Med. 1911;14(2):148-158.
3. Barringer BS. Radium in the treatment of carcinoma of the bladder and prostate. JAMA. 1917;68(17):1227-1230.
4. Young HH. Early diagnosis and radical cure of carcinoma of the prostate. Bull Johns Hopkins Hosp. 1905;16:314-321.
5. Huggins C, Hodges CV. Studies on prostatic cancer II: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209-223.
6. Gleason DF, Mellinger GT. Predication of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol. 1974;111(1):58-64.
7. Stamey TA, Yang N, Hay AR, McNeil JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909-916.
8. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156-1161.
9. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
10. Smith RA, Cokkinides, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin. 2008;58(3):161-179.
11. Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate specific antigen test among US men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17(3): 636-644.
12. Ries LAG, Melbert D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2005. Surveillance, Epidemiology, and End Results. Bethesda, MD: National Cancer Institute; 2008.
13. Merrill RM, Weed DL. Measuring the health burden of cancer in the United States through lifetime and age-conditional risk estimates. Ann Epidemiol. 2001(8);11:547-533.
14. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Krusemo UB, Kraaz W. Natural history of localized prostatic cancer. A population-based study in 223 untreated patients. Lancet. 1989;1(8642):799-803.
15. Johansson JE, Adami HO, Andersson SO, Bergrstrom R, Holmberg L, Krusemo UB. High 10 year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267(16):2191-2196.
16. Johansson JE, Holmberg JS, Bergrstrom R, Adami HO. Fifteen year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997;277(6):467-471.
17. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291(22):2713-2719.
18. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330(4): 242-248.
19. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280(11): 975-980.
20. Albertsen PC, Hanley JA, Fine J. 20 year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095-2101.
21. Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011;60(3):554-563.
22. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150(2, pt 1):379-385.
23. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224.
24. Epstein JI. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy. Am J Surg Pathol. 2000;24(4):477-478.
25. Berney DM, Fisher G, Kattan MW, et al. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathologic diagnosis and grading. BJU Int. 2007;100(6):1240-1244.
26. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97(17):1248-1253.
27. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302(11):1202-1209.
28. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29(10):1335-1341.
29. Draisma G, Boer R, Otto SJ, et al. Lead times and over detection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868-878.
30. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-1319.
31. Schroeder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
32. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomized population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-732.